Revenio Group Oyj - Changes board/management/auditors

Revenio Group Corporation: Revenio appointed Robin Pulkkinen as CFO

Revenio Group Corporation, Stock Exchange Release, June 3, 2015 at 16:30


Revenio appointed Robin Pulkkinen as CFO

Revenio Group Corporation has appointed M.Sc. Econ. Robin Pulkkinen (born 1980)
as CFO and member of the management group as of July 15, 2015. Pulkkinen reports
to the Revenio Group's President and CEO Olli-Pekka Salovaara.

Pulkkinen  joins Revenio from the  position of Symbio's EMEA  area CFO. Prior to
Symbio  Pulkkinen  has  held  several  top management positions in international
corporations both in Finland and Canada having solid experience in various roles
of financial management."I  am pleased to have  Robin Pulkkinen joining us  as the group CFO. Robin will
bring  us a wealth of international financial management view. His experience of
the  North American business  culture is also  very important to us, considering
the significance of the US market to Revenio and health tech in general," states
Olli-Pekka Salovaara.

Attachments: Robin Pulkkinen's CV and picture.

For further information, please contact:
President & CEO Olli-Pekka Salovaara, tel. +358 40 567 5520
olli-pekka.salovaara@revenio.fi
www.revenio.fi

DISTRIBUTION:
NASDAQ OMX Helsinki
Financial Supervisory Authority (FIN-FSA)
Principal media
www.revenio.fi

The Revenio Group in brief

Revenio is a Finnish health tech group whose core business is in tonometers. The
Revenio Health Tech segment comprises the business operations of Icare Finland
Oy, Revenio Research Oy and Oscare Medical Oy, which specializes in osteoporosis
screening and monitoring. The common denominators of Revenio's business
operations include screening, follow-up and the global need to make cost savings
in health care via preventive measures. Revenio seeks vigorous growth in health
technology, both organically and through acquisitions and mergers. Revenio aims
at developing even more efficient and easily adopted methods for the early-stage
detection of diseases with significance for public health. The focus of
Revenio's screening technology lies on the early detection of glaucoma,
osteoporosis, skin cancer and asthma, and the monitoring of these during the
treatment process.

In 2014, the Revenio Group's net sales totaled MEUR 16.0, with its operating
profit (EBIT) from continuing operations standing at 27.5%. The Revenio Group
Corporation is listed on NASDAQ OMX Helsinki. www.revenio.fi


[HUG#1926096]

Attachments:

Robin Pulkkinen CV.pdf